Fig 1.
Schematic diagram of the longitudinal study design.
Both plasma and saliva were collected for evaluation using liquid biopsy. For example, T2 samples were used to estimate the therapeutic effect of surgery based on T1 sampling data, and T3 samples were used to evaluate the efficiency of adjuvant therapies based on sampling T2 sampling data.
Table 1.
Summarized clinical information from patients enrolled in the longitudinal liquid biopsy study for the detection of oral squamous cell carcinomas.
Fig 2.
Oncoplot of the top 20 genes analyzed by whole-exome sequencing from the index tumors of 11 patients.
Sequencing depth was 200 x for the index tumor, and 100 x for whole blood.
Fig 3.
Clinical progress of recurrence and non recurrence group.
Mean allele frequency (MAF) and ctDNA count differences between plasma and saliva based on liquid biopsy examinations. A and B. Clinical monitoring of both recurrence group (A) and non recurrence group (B), C. A swimmer plot to track the occurrence of mutations in patients over time. The purple triangle indicates the detection of ctDNA. D. MAF of both plasma and saliva samples,Sum of ctDNA counts in both plasma and saliva.
Table 2.
Summary of longitudinal ctDNA detection results and clinical recurrence.
Table 3.
Summary of surveillance of oral squamous cell carcinoma recurrence by longitudinal liquid biopsy.
Fig 4.
Concordance between cfDNA and index tumors.
A. Summarized concordance between plasma and saliva samples, B. Summarized gene-based concordance.